What type of cancer is larotrectinib mainly indicated for?

Larotrectinib is a highly selective TRK inhibitor, mainly used to treat patients with solid tumors carrying NTRK gene fusions. Different from traditional treatment methods classified by organs, larotrectinib is a "tissue-agnostic" anti-cancer drug, that is, no matter what tissue or organ the tumor originates from, as long as NTRK fusion mutations are detected, patients may benefit from this targeted therapy. This precision treatment concept creates a new model of cancer treatment.

NTRKGene fusion is a rare but clear type of oncogenic driver mutation that may appear in a variety of solid tumors, such as infantile fibrosarcoma, salivary gland cancer, thyroid cancer, breast cancer, lung cancer, colorectal cancer, etc. Larotrectinib can effectively inhibit abnormal signaling triggered by the fusion protein, thereby preventing tumor growth. Clinical studies have shown that larotrectinib exhibits high objective response rates in different tumor types and has long-lasting efficacy. It is especially suitable for patients who have failed traditional treatments or have metastasized.

Compared with other anticancer drugs, larotrectinib is relatively well tolerated, and adverse reactions are usually mild, such as fatigue, dizziness, nausea, elevated transaminases, etc. Most patients can continue to complete treatment without interrupting medication. This also makes larotrectinib particularly suitable for use in children or patients with weak health. It is especially widely used in children with soft tissue sarcomas or rare tumors, improving the lack of effective treatment options for such patients in the past.

To sum up, the main indication of larotrectinib is to treat patients with various solid tumors carrying NTRK fusion mutations. It is not restricted by the primary site of the tumor. It is one of the first targeted drugs approved for "tissue-agnostic" indications. With the development of genetic testing technology, more and more patients can confirm their NTRK fusion status through testing, thereby receiving personalized and precise treatment. In the future, larotrectinib is expected to be widely used in more NTRK-related cancers.

Reference materials:https://www.vitrakvi.com/